| Synonym |
| Thai / English name |
Part Used : -Activity : CYP2C19 INHIBITIONSolvent/Active Compound : petroleum ether extract, EupatorinType of experiment : in vitroType of animal : otherType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark :Note : Andrographis paniculata (AP) ethanol extract and Centella asiatica (CA) dichloromethane extract exhibited mixed type inhibition towards CYP2C19 with Ki values of 67.1 and 16.4 microgram/ml respectively; CA ethanol extract and Orthosiphon stamineus (OS) petroleum ether extract competitively CYP2C19 activity (Ki =39.6 and 41.5 microgram/ml respectively). Eupatorin (a major active constituent of OS) was found to significantly inhibit CYP2C19 by mixed type inhibition (Ki=7.1 microgram/ml or 20.6 micromolar
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : aqueousType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = 835.5 microgram/ml
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : methanolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = 231.5 microgram/ml
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : dichloromethane extractType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = > 250 microgram/ml
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : petroleum ether extractType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = > 67.1 microgram/ml
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : rosmarinic acidType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = 816.3 microgram/ml (2265.5 micromolar)
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : caffeic acidType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = > 1,000 microgram/ml (> 5550.7 micromolar)
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : sinensetinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = 71.6 microgram/ml (192.3 micromolar)
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : eupatorinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : - IC50 = 12.1 microgram/ml (35.1 micromolar) - Strong inhibition was observed with eupatorin, the major O. stamineus constituent. Therefore care should be taken when these O. stamineus components are co-administered with CYP2C19 substrates (such as omeprazole, proguanil, barbiturates, citalopram, and diazepam)
